BMYMP News and Press, Bristol-Myers Squibb $2Pr From 03/18/24

2024-03-18 12:28:56 ET Summary Schwab U.S. Dividend Equity ETF™ has undergone a major change in its holdings, eliminating and replacing 23 stocks contributing 1/5 of its dividend. Four of the added stocks are flagged as very risky by Seeking Alpha's Quant rating system...

2024-03-14 11:02:09 ET Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference March 14, 2024 08:30 a.m. ET Company Participants Lynelle Hoch - President of Cell Therapy Wendy Short Bartie - Senior Vice President, U.S. Hematology and Onco...

2024-03-13 13:07:10 ET Bristol-Myers Squibb Company (BMY) Leerink Partners Global Biopharma Conference 2024 Conference Transcript March 13, 2024, 10:00 AM ET Executives Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development Tim Power - Inv...

2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....

2024-03-07 14:32:17 ET Summary Bristol-Myers Squibb might have seen a price decline over the past year, but it now boasts of a superior dividend yield and competitive P/E ratio compared to peers. After a revenue setback on the patent erosion of its cancer treatment drug, it's now ...

2024-02-25 10:00:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...

2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...

2024-02-18 06:39:11 ET Summary This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February. ... ...

2024-02-16 15:11:53 ET Summary I created a U.S. stock portfolio in mid-2023 that has outperformed with a 24% total return vs 17% for the S&P 500. I address valuation concerns for the U.S. market and include dividend growers and international stocks in the portfolio. The co...

2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...